Username:

Password:
 
ABOUT HIV PREVENTION TREATMENT NEWS COMMUNITY ABOUT US EN ESPAÑOL POZ MAGAZINE

Back to home » News & Views » Treatment News

 
February 29, 2008
GSK Comments on ACTG 5202 Study Changes
HIV Treatment Increases Survival, Not Heart Attack Risk
February 28, 2008
Epzicom Efficacy Concerns Lead to ACTG Study Changes
February 27, 2008
Safe for Some to Switch to Viramune With Higher CD4 Counts
February 26, 2008
New Prezista 600 mg Tablet Approved
GeoVax Vaccine to Move Forward
February 25, 2008
Growth Hormone Boosts Thymus T-Cell Production
February 22, 2008
Discordant Responders Have Faster Disease Progression
February 21, 2008
Drug Use Linked to Infection With Resistant Virus
February 20, 2008
Dipstick Kidney Test Less Accurate in HIV
Study Links Zerit and Retrovir With Diabetes Risk
February 19, 2008
Starting Treatment With Higher CD4s Cuts Death Rate
February 15, 2008
HIV Treatment Improves, but Doesn’t Restore, B Cells
February 14, 2008
Suppressing HIV Improves Kidney Function
February 13, 2008
Acyclovir Doesn’t Reduce HIV Infection Risk in HSV-2-Positive People
February 12, 2008
Extended-Release Viramune Begins Study
VIRxSYS Gene Therapy Makes Progress
Women & HIV Treatment
World of Prevention: Vaccines and More
Condom-Free Sex? Controversial Swiss Declaration
February 11, 2008
New Hope for Treatment Experienced
February 09, 2008
Prezista Effective and Safe in Positive Kids
Durable Efficacy and Safety With Isentress Treatment
Good Bacteria Reduces Vaginal HIV Levels
February 08, 2008
HIV & Your Heart: Part I
HIV & Your Heart: Part II
Morris Jackson: Survivor and Treatment Activist
February 07, 2008
Prevention and Women: HIV-positive and HIV-negative
Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosing
Durable Efficacy Seen in Studies of New NNRTI Intelence
Nanotechnology May Yield Long-Lasting Meds
February 06, 2008
Male Circumcision Doesn't Reduce Women's HIV Risk
TDM-Guided PI Dose Increases of Limited Benefit
Refining HIV Treatment for New Med Takers
February 05, 2008
AIDS Survival: Progress Not Perfection
Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potency
Epzicom Comparable to Truvada as First-Line NRTI Choice
February 04, 2008
Vicriviroc Shows Well in Treatment-Experienced Patients
Abacavir, Didanosine Linked to Increased Heart Attack Risk
Norvir/Reyataz Comparable to Kaletra for First-Line Therapy
Sexual Reinfection With HCV Following Treatment
February 01, 2008
Parasitic Drug Shows HIV-Fighting Promise
Gilead Loses Key Patents on Tenofovir

 

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
 






Michelle



Glenn



Hilary
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy